Email
Print
Asthma & COPD Drugs Market Overview
Asthma & COPD Drugs Market size is estimated to reach $42.1 billion by 2027, growing at a CAGR of 4.7% during the forecast period 2022-2027. Asthma & COPD Drugs have the principal goal to reverse bronchoconstriction which is hindering the airway to enhance air flow in and out of the lungs. Bronchodilators are principal in the treatment of airways ailments. They are the backbone of the present handling of chronic obstructive pulmonary disease (COPD) and are crucial in the symptomatic handling of asthma, though controversies around the application of these medications prevail. Anticholinergics have vital applications as bronchodilators for the treatment of obstructive airway ailments like both asthma and, more specifically, chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS), also termed inhaled steroids, are the most powerful anti-inflammatory controller medicines accessible presently for asthma regulation and are utilized to reduce the frequency and severity of asthma symptoms. The current application of omalizumab in asthma offers a good example on the possible therapeutic role of monoclonal antibodies in both asthma and COPD. There are numerous additional monoclonal antibodies which are presently examined as potential therapies in these ailments. The principal kinds of anti inflammatories for superior asthma regulation are steroids or corticosteroids. Additional anti-inflammatory treatments involve leukotriene modifiers, anticholinergics and immunomodulators. The development of drugs for asthma and COPD in the Asthma & COPD Drugs industry in the U.S. includes regulatory oversight and clearance, the particulars of which are not recognizable to numerous prescribers.
The expanding population of the elderly requiring application of oral and inhaled corticosteroids for the treatment of acute asthma and COPD (Chronic Obstructive Pulmonary Disorder) is set to drive the Asthma & COPD Drugs Market. The heightened progress in respiratory diseases therapy and soaring count of novel product launches are set to propel the growth of the Asthma & COPD Drugs Industry during the forecast period 2022-2027. This represents the Asthma & COPD Drugs Industry Outlook.
Asthma & COPD Drugs Market Report Coverage
The “Asthma & COPD Drugs Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Asthma & COPD Drugs Market.
Key Takeaways
- Geographically, Europe (Asthma & COPD Drugs Market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of respiratory ailments and extensive application of inhaled corticosteroids for the treatment of asthma in the North American region.
- Asthma & COPD Drugs Market growth is being driven by the increasing predominance of asthma and chronic obstructive pulmonary disorder (COPD) requiring the application of anticholinergics and surging technological progress across the world. However, the raised setup cost and soaring maintenance are some of the major factors hampering the growth of Asthma & COPD Drugs Market.
- Asthma & COPD Drugs Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Asthma and COPD Drugs Market report.
Asthma & COPD Drugs Market Segment Analysis - By Drug Class
The Asthma & COPD Drugs Market based on drug class can be further segmented into Bronchodilators, Anti-inflammatory Drugs,
Monoclonal Antibodies, Combination Drugs. The Combination
Drugs Segment held the
largest Asthma & COPD Drugs market share in 2021. This growth is owing
to the heightening application of combination drugs attributed to the
reliability of combination therapy. Combination inhalers are accessible for the
treatment of Chronic Obstructive Pulmonary Disorder (COPD) as per the recommendation
of the physician. When inhaled
corticosteroids (ICS) are prescribed for COPD, it is suggested to take them
with bronchodilators. The two medications are typically available in
combination inhalers. The surging application of combination drugs for the
treatment of COPD is therefore further propelling the growth of the Combination
Drugs segment.
Furthermore, the Anti-inflammatory Drugs segment is estimated to grow with the fastest CAGR of 5.7% during the forecast period 2022-2027 owing to the soaring application of inhaled corticosteroids for the treatment of asthma and the surging progress in therapy.
Asthma &
COPD Drugs Market Segment Analysis - By Indication
The Asthma & COPD Drugs Market based on indication can be further segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD). The Asthma Segment held the largest Asthma & COPD Drugs market share in 2021. This growth is owing to the increasing pervasiveness
of Asthma across the world attributed to the raised count of cigarette smokers
worldwide. Inhaled corticosteroids (ICS), by way of
their anti-inflammatory impacts have been the chief support of treatment of
asthma for numerous years. In the last twenty years, knowledge of the
mechanisms of the inflammatory processes fundamental to asthma evolved at an
accelerated pace, numerous key mediators (cytokines and receptors) were recognized,
and the laboratory methods have permitted to synthesize monoclonal antibodies greatly
particular for those target molecules. The huge financing in the investigation
of asthma drugs together with strategic collaborations like mergers and
acquisitions are further propelling the growth of this segment.
Furthermore, the Chronic Obstructive Pulmonary Disease (COPD) segment is estimated to grow with the fastest CAGR of 5.3% during the forecast period 2022-2027 owing to the rising predominance of chronic obstructive pulmonary disorder (COPD) attributed to the proliferating exposure to cigarette smoke, air pollution, chemical fumes or dust and rare genetic conditions amidst other factors.
Asthma & COPD Drugs Market Segment Analysis - By Geography
The Asthma & COPD Drugs Market based on geography can be further segmented into North America, Europe,
Asia-Pacific, South America and Rest of the World. North America (Asthma & COPD Drugs Market) held the largest Asthma & COPD Drugs market share with
36% of the overall market in 2021. This growth is owing to the
increasing predominance of asthma and chronic obstructive pulmonary disorder
(COPD) requiring the application of inhaled corticosteroids in the North
American region. Application of nonsteroidal anti inflammatories like
nonsteroidal anti-inflammatory drugs (NSAIDs) for asthma may be dangerous. The heightening
R&D activities and the existence of key players are further propelling the
growth of the Asthma & COPD Drugs Industry, thereby contributing to the Asthma & COPD Drugs Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the emerging awareness regarding Asthma and Chronic Obstructive Pulmonary Disorder (COPD) in the Asia-Pacific region. The extensive application of bronchodilators in countries like China with a considerable population of smokers together with the surging count of hospitals offering services to an enormous patient pool is further fueling the progress of the Asthma & COPD Drugs Market in the Asia-Pacific region.
Asthma & COPD Drugs Market Drivers
Surging Applications of Anticholinergics for Treatment of Asthma and Chronic Obstructive Pulmonary Disorder (COPD) are Projected to Drive the Growth of Asthma & COPD Drugs Industry:
Anticholinergics have significant applications as bronchodilators for the treatment of obstructive airway ailments, both asthma and, more specifically, chronic obstructive pulmonary disease (COPD). Those in certified clinical application are synthetic quaternary ammonium congeners of atropine and involve ipratropium bromide, oxitropium bromide and tiotropium bromide, each of which is very unsatisfactorily absorbed when provided by inhalation. Ipratropium and oxitropium have comparatively brief durations of action (4-8 h). They have been extensively utilized for numerous years, either alone or in integration with short-acting beta-adrenergic agents like albuterol and fenoterol, for both maintenance treatment of stable ailment and for acute intensifications of airway obstruction. Tiotropium, which was presented in the early 2000s, has a duration of action of at least 1-2 days making it appropriate for once-daily maintenance treatment of Chronic Obstructive Pulmonary Disorder (COPD). All of the above agents have an extensive therapeutic margin and are secure and well tolerated by patients. The surging applications of Anticholinergics as bronchodilators for treatment of Asthma and COPD are therefore fueling the growth of the Asthma & COPD DrugsIndustry, thereby contributing to the Asthma & COPD Drugs
Soaring Applications of Monoclonal Antibodies for Asthma and Chronic Obstructive Pulmonary Disorder (COPD) are Expected to Boost the Growth of the Asthma & COPD Drugs Market:
Presently, greater than 60 monoclonal antibodies have been approved for clinical therapeutic application. In asthma and chronic obstructive pulmonary disease (COPD), the inflammation in the airways cannot always be regulated with traditional therapies, like inhaled corticosteroids. Inclusion of more particular anti-inflammatory therapies, like monoclonal antibodies, against inflammation pathways may enhance the disease result. As per expert opinion, the present application of omalizumab in asthma offers a good example on the possible therapeutic role of monoclonal antibodies in both asthma and COPD. There are numerous additional monoclonal antibodies which are presently investigated as potential therapies in these ailments. The recognition of the disease subsets in which these kinds of antibodies might apply the maximum advantage opens the door for personalized medicine and for targeted biological therapy in asthma and COPD. The soaring applications of Monoclonal Antibodies for Asthma and Chronic Obstructive Pulmonary Disorder (COPD) are therefore driving the growth of the Asthma & COPD Drugs Market during the forecast period 2022-2027.
Asthma & COPD Drugs Market Challenges
Challenges of Chronic Obstructive Pulmonary Disorder (COPD) Diagnosis are Hampering the Growth of the Asthma & COPD Drugs Market:
Chronic obstructive pulmonary disease (COPD) is a principal cause of demise globally and this burden is estimated to rise unless exposure to risk factors is attended to. As per World Health Organization (WHO), Chronic obstructive pulmonary disease (COPD) is the third principal cause of demise globally, bringing about 3.23 million demises in 2019 and almost 90% of COPD demises in those under 70 years of age happen in low- and middle-income countries (LMIC). Diagnosis of COPD is a challenge: COPD is underdiagnosed and repeatedly misdiagnosed for asthma or other respiratory conditions. Though spirometry is only one parameter for establishing a clinical diagnosis of COPD, dearth of routine spirometry is an essential cause of COPD misdiagnosis. Differential diagnosis from asthma is vital owing to the treatment strategies for and progression and results of, the two conditions differing considerably. These issues are thus hampering the growth of the Asthma & COPD Drugs Market.
Asthma & COPD Drugs Industry Outlook
Novel product launches, mergers and acquisitions, joint ventures, collaborations, partnerships, expansion strategies and R&D activities are key strategies adopted by players in the Asthma & COPD Drugs Market. The top 10 companies in the Asthma & COPD Drugs market are:
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Novartis AG
- Abbott Laboratories
- Hoffmann-La Roche Ltd
- Sanofi
- Teva Pharmaceutical Industries Ltd
- E Vectura Group Plc
Recent Developments
- In July 2021, Philip Morris International (PM) consented to acquire Vectura Group, an innovative inhaled drug delivery solutions provider, in an all-cash deal of nearly $1.2 billion. The deal was anticipated to close in the second half of 2021, subject to shareholders’ vote and regulatory approvals. Based in New York, Philip Morris makes and markets cigarettes, tobacco, nicotine-including products, smoke-free products and connected electronic devices and accessories in over 180 countries.
- In June 2021, Novartis and Molecular Partners declared the beginning of their EMPATHY Phase II/III Investigation to analyze the application of its DARPin (Designed Ankyrin Repeat Proteins) therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will reportedly perform the trial program with Molecular Partners acting as sponsor. The EMPATHY clinical trial program is aimed to examine the security and efficiency of ensovibep in COVID-19 in the initial phases of infection, with the objective of worsening symptoms and hospitalization.
- In December 2020, Vectura Group plc, declared an extension of its capacities to manage and establish greatly powerful active pharmaceutical ingredients (HPAPIs) at its facility in Chippenham, U.K. The project will involve the installation of six novel containment isolators, housing development manufacturing machinery for dispensing, blending, co-milling, jet-milling, spray-drying and blister-filling, into a newly-modelled product development manufacturing laboratory. The novel facility will boost the containment capacities at the site, and permit Vectura scientists to securely manage APIs with an occupational exposure limit (OEL) as lirrle as 0.1 µg/m3. This concludes the Asthma & COPD Drugs Industry Outlook.
Relevant Reports:
Report Code: HCR 84738
Report Code: HCR 1217
Report Code: HCR 0369
For more Lifesciences and Healthcare Market reports, please click here